HBM Partners related stories
All articles and analysis
Numab Therapeutics lands $110m Series CNumab Therapeutics AG, a clinical stage biopharmaceutical company, has raised about $110 million in Series C financing.
Hookipa Pharma debuts IPONew York and Austria-based Hookipa Pharma, a developer of immunotherapeutics, has raised $84 million for its IPO after pricing its 6 million shares at $14 per share. The stock began trading April 18, 2019 on the NASDAQ under the ticker symbol “HOOK." BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the lead underwriters. Hookipa's pre-IPO backers included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
- Gynesonics raises $75 mln
Gynesonics said Jan. 3 that it raised $75 million in equity financing led by Bain Capital Life Sciences. Gynesonics existing investors, including Abingworth, Advanced Technology Ventures (ATV), Endeavour Vision, HealthCrest, InterWest Partners, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital also participated in the round. Gynesonics, of Redwood City, California, is developing treatments for uterine conditions.
- MPM Capital leads Series B round for iTeos Therapeutics
iTeos Therapeutics, a Belgian biopharmaceutical company, has raised 64 million euros ($74 million) in Series B funding. MPM Capital led the round which included HBM Partners, 6 Dimensions Capital, Curative Ventures and VIVES Louvain Technology Fund.
- Hookipa Biotech scores $59.6 mln Series C
Hookipa Biotech AG, an Austrian clinical stage biotech company, has raised $59.6 million in Series C financing. The investors included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
- VC-backed Allena debuts IPO
Newton, Massachusetts-based Allena Pharmaceuticals, a developer of treatments for patients with rare and severe metabolic and kidney disorders, has raised about $75 million for its IPO after pricing its over 5.3 million share at $14 per share. The stock began trading November 2, 2017 on the NASDAQ under the ticker symbol "ALNA." Credit Suisse, Jefferies and Cowen are the lead underwriters. Allena's investors included Frazier Healthcare, Bessemer Venture Partners, HBM Partners, Fidelity and Partner Fund Management.
- Allena Pharmaceuticals nabs $53 mln Series C
Newton, Massachusetts-based Allena Pharmaceuticals, a biopharmaceutical company focused on treating metabolic and orphan diseases, has closed $53 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Fidelity Management & Research Company, Wellington Management Company, Frazier Healthcare, HBM BioCapital and Pharmstandard International S.A.
- Gynesonics pulls in $43 mln
Redwood City, California-based Gynesonics, a women's healthcare company focused on developing solutions for treating uterine fibroids, has secured $43 million in funding. Endeavour Vision and Abingworth led the round with participation from HealthCrest, InterWest Partners, Advanced Technology Ventures, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.
- Symbiomix Therapeutics racks up $41 mln
Newark, New Jersey-based Symbiomix Therapeutics, which develops medicines for serious women's health infections, has received the final tranche of its $41 million Series A round. The investors included OrbiMed, Fidelity BioSciences and HBM Partners.
- Allena Pharma raises $25 mln
Allena Pharmaceuticals has completed a $25 million Series B financing led by HBM Partners. Existing investors Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners and new investor Pharmstandard International also participated. Newton, Mass.-based Allena is specialty biopharmaceutical company that develops non-systemic protein therapeutics to treat metabolic and orphan diseases.